Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Rivoltini

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|November 1, 1995
HLA associations in the antitumor response against malignant melanomaF M Marincola, P Shamamian, L Rivoltini, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 1, 1998
Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killingL Rivoltini, M Radrizzani, P Accornero, et al.
Melanoma Research|October 24, 2002
Cytotoxic T-lymphocyte responses in melanoma through in vitro stimulation with the Melan-A peptide analogue A27L: a qualitative analysisB Palermo, R Campanelli, S Garbelli, et al.
Critical Reviews in Immunology|January 7, 1998
Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivityL Rivoltini, D J Loftus, P Squarcina, et al.
Targeted Oncology|September 19, 2014
Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg)M Donini, S Buti, S Lazzarelli, et al.
Cell Death & Disease|March 4, 2011
Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cellsM L Marino, S Fais, M Djavaheri-Mergny, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|May 1, 1996
Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesionsF M Marincola, Y M Hijazi, P Fetsch, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 23, 1997
Calcium ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cellsB J Czerniecki, C Carter, L Rivoltini, et al.
British Journal of Cancer|August 8, 2014
Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapyM Tazzari, T Negri, F Rini, et al.
Human Gene Therapy|December 28, 1999
Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cellsF Arienti, F Belli, F Napolitano, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|November 1, 1995
HLA associations in the antitumor response against malignant melanomaF M Marincola, P Shamamian, L Rivoltini, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 1, 1998
Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killingL Rivoltini, M Radrizzani, P Accornero, et al.
Melanoma Research|October 24, 2002
Cytotoxic T-lymphocyte responses in melanoma through in vitro stimulation with the Melan-A peptide analogue A27L: a qualitative analysisB Palermo, R Campanelli, S Garbelli, et al.
Critical Reviews in Immunology|January 7, 1998
Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivityL Rivoltini, D J Loftus, P Squarcina, et al.
Targeted Oncology|September 19, 2014
Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg)M Donini, S Buti, S Lazzarelli, et al.
Cell Death & Disease|March 4, 2011
Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cellsM L Marino, S Fais, M Djavaheri-Mergny, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|May 1, 1996
Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesionsF M Marincola, Y M Hijazi, P Fetsch, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 23, 1997
Calcium ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cellsB J Czerniecki, C Carter, L Rivoltini, et al.
British Journal of Cancer|August 8, 2014
Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapyM Tazzari, T Negri, F Rini, et al.
Human Gene Therapy|December 28, 1999
Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cellsF Arienti, F Belli, F Napolitano, et al.
Pageof 9